Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

Migraine displays clinical heterogeneity of attack features and attack triggers.

The question is whether this heterogeneity is explained by distinct intracellular signaling pathways leading to attacks with distinct clinical features.

One well-known migraine-inducing pathway is mediated by cyclic adenosine monophosphate and another by cyclic guanosine monophosphate.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.

Each person switched between CGRP (Calcitonin Gene-Related Peptide) and the comparison at some point, usually with a gap in between.

Data on headache intensity, characteristics and accompanying symptoms were collected until 24 hours after drug administration.

What Was Measured

PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Migraine Disorders, Signal Transduction, Sildenafil Citrate and Vasodilator Agents.

The authors tagged it with the keywords CGRP, cAMP, cGMP, headache, intracellular signaling pathway and provocation.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Cephalalgia : an international journal of headache), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.